期刊文献+

氢氯噻嗪对高血压患者肾素-血管紧张素-醛固酮系统及生化指标的影响 被引量:5

Effects of Hydrochlorothiazide on Variety of Renin-angiotensin-aldosterone System and Biochemical Parameters in Hypertensive Patients
原文传递
导出
摘要 目的:观察不同剂量氢氯噻嗪(HCTZ)对原发性高血压患者肾素-血管紧张素-醛固酮系统(RAAS)活性及生化指标的影响。方法:选择2009年1月-2010年7月在我院治疗的120例轻、中度高血压患者,随机分为3组:对照组(A组)、HCTZ12.5mg组(B组)和HCTZ25.0mg组(C组)。A组:给予苯磺酸氨氯地平5mg,口服,qd;B组:在A组基础上加用HCTZ12.5mg,口服,qd;C组:在A组基础上加用HCTZ25.0mg,口服,qd。6周后比较各组患者血清RAAS活性和生化指标。结果:B组的血管紧张素Ⅱ(AngⅡ)和醛固酮(ALD)浓度较A组高(P<0.05),血钾、血钠浓度下降不明显,血糖未见明显变化(P>0.05);C组血浆肾素(PRA)、AngⅡ和ALD较B组高(P<0.05),血钾、血钠浓度下降,血糖增高。结论:12.5mg的HCTZ即能激活RAAS活性,25.0mg的HCTZ对生化指标有较大影响。 OBJECTIVE:To observe the effects of different concentrations hydrochlorothiazide on variety of renin-angiotensin-aldosterone system and biochemical parameters in hypertensive patients.METHODS:120 cases with mild to moderate hypertension received medical treatment in our hospital during 2009.1-2010.7 They were randomly divided into 3 groups:control group(group A),HCTZ 12.5 mg group(group B) and HCTZ 25.0 mg group(group C).A group:40 patients received 5 mg amlodipine,oral once every day;group B:5 mg amlodipine+12.5 mg HCTZ;group C:5 mg amlodipine +25.0 mg HCTZ.After 6 weeks,the RAAS activity and biochemical parameters of 3 groups were compared.RESULTS:The AngⅡ and ALD in serum of group B after treatment was higher than that of group A(P〈0.05).Serum potassium,serum sodium and blood glucose did not change significantly.The AngⅡand ALD in serum of group C was higher than that of group B(P〈0.05).Serum potassium and serum sodium was lower.Blood glucose was higher.CONCLUSION:12.5 mg HCTZ can activate the RAAS activity and 25.0 mg HCTZ has greater effect to biochemical parameters.
机构地区 河南省中医院
出处 《中国药房》 CAS CSCD 北大核心 2011年第4期352-354,共3页 China Pharmacy
关键词 肾素-血管紧张素-醛固酮系统 血糖 血钾 Renin-angiotensin-aldosterone system Glucose Potassium
  • 相关文献

参考文献7

二级参考文献54

  • 1刘军兴.小剂量氢氯噻嗪与卡托普利联合应用治疗糖尿病性高血压的临床观察[J].中国医院药学杂志,2004,24(9):558-559. 被引量:3
  • 2李云,吴寿岭,高润芝,王黎光,李东贤,刘克俭,侯国盛,周永.氢氯噻嗪对不同血管紧张素转化酶基因型高血压患者血浆血管紧张素转化酶血管紧张素Ⅱ浓度的影响[J].临床心血管病杂志,2005,21(7):405-407. 被引量:10
  • 3孙宁玲,荆珊,陈捷.厄贝沙坦/氢氯噻嗪复方片剂治疗中国高血压病患者的达标率分析[J].中华心血管病杂志,2005,33(7):618-621. 被引量:108
  • 4赵海燕,吴寿岭,孙立霞,李云,侯国盛,刘福山,王黎光,吴云涛.氢氯噻嗪与螺内酯、卡托普利联合治疗原发性高血压[J].高血压杂志,2006,14(1):23-27. 被引量:23
  • 5Gress TW, Nielo FJ, Shahar E, et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atheroselerosis risk in communities study[J]. N Engl J Med, 2000, 342: 905-912.
  • 6Lenfant C, Chobanian AV, Jones DW, et al. Seventh report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure(JNC 7): resetting the hypertension sails[J].Hypertension, 2003, 41:1178-1179.
  • 7Hansson L,Lindhom LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Catopril Prevention Project (CAPPP) randomized trial [J]. Lancet, 1999, 353:611- 616.
  • 8Chobnian AV, Bakris GI, Black HR, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee.The seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure [J]. Hypertension, 2003,42: 1206-1052.
  • 9Messerli FH, Bangalore S, Juius S. Risk/benefit assessment of beta- blockers and diuretics precludes their use for first-line therapy in hyprtension[J].Circulation, 2008, 117:2706-2715.
  • 10Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihyper- tensive drugs: a network meta-analysis [J]. Lancet, 2007,369:201-207.

共引文献20

同被引文献39

引证文献5

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部